FAKTOR-OPTIONSSCHEIN - BIONTECH ADR Stock

Certificat

DE000SF30757

Delayed Deutsche Boerse AG 04:01:33 2024-05-22 EDT
0.045 EUR +2.27% Intraday chart for FAKTOR-OPTIONSSCHEIN - BIONTECH ADR
Current month+4.76%
1 month+7.32%
Date Price Change
24-05-22 0.045 +2.27%
24-05-21 0.044 -2.22%
24-05-20 0.045 +4.65%
24-05-17 0.043 -4.44%
24-05-16 0.045 0.00%

Delayed Quote Deutsche Boerse AG

Last update May 22, 2024 at 04:01 am

More quotes

Static data

Product typeExotische Produkte
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Société Générale Société Générale
WKN SF3075
ISINDE000SF30757
Date issued 2021-08-30
Strike 369 $
Maturity Unlimited
Parity 1 : 1
Emission price 2
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 2.11
Lowest since issue 0.039
Spread 0.01
Spread %18.18%

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
84.8 EUR
Average target price
105.4 EUR
Spread / Average Target
+24.28%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW